Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about a paper he co-authored with F. Anthony Greco, published in the Journal of Clinical Oncology:
“Hot off the press! Pleased to share our commentary in the Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO) flagship journal.
Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?
Our commentary argues it’s time to retire the 50-year-old CUP paradigm.
The evidence:
- Molecular profiling identifies tissue origin in 80-90% of CUP cases
- NGS finds actionable mutations in 30-40%
These patterns mirror known primary lung, GI, breast, and ovarian cancers
Our proposal: A molecular-first classification that prioritizes actionable alterations over anatomic origin. Biology, not anatomy, should drive treatment.
CUP forces us to confront a truth across ALL oncology: molecular heterogeneity transcends organ boundaries. Precision Oncology CUP Cancer Research
Read the full commentary and share your comments.”
Title: Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?
Authors: Vivek Subbiah and F. Anthony Greco
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Vivek Subbiah.